Technical Update of Inspection of Licensed and Unlicensed Blood Banks, Brokers, Reference Laboratories, and Contractors
![Bioburden - Live Online Training](files/eca/userImages/training.img/Z-ECA-Bioburden-LOT.jpg)
Recommendation
15/16 October 2024
Regulatory Expectations and Practical Experiences
In October 2012, the US FDA implemented the Compliance Program Guidance Manual, Chapter 42 - Blood and Blood Products "Inspection of Licensed and Unlicensed Blood Banks, Brokers, Reference Laboratories, and Contractors- 7342.001". Now this document was technically updated.
This program represents a continuing compliance and surveillance activity that began in 1972. The program objective is to ensure that blood and blood components for human use are safe, pure, effective, and are appropriately labeled. The inspection of a blood establishment is supposed to ensure that manufacturers are making products that:
- Meet the standards described in applicable provisions of the regulations, including those specifically intended to protect donors. These include regulations in Title 21, Code of Federal Regulations (21 CFR) Parts 600, 601, 606, 607, 610 and 640, process and production controls, equipment regulations and quality control in 21 CFR Part 211 and other applicable standards, and
- Meet any additional conditions of licensure incorporated in the establishment's approved Biologic License Application (BLA), if manufacturing a licensed product.
The following types of establishments are covered by this program:
- Blood Bank (foreign and domestic)
- Blood and/or Plasma Broker
- Component Preparation Facility
- Contractor
- Distribution Center or Depot
- Donor (collection) Center
- Hospital Transfusion Service
- Indian Health Service Hospital
- Military Blood Banks and Transfusion Service
- Testing Laboratory
- Veteran's Health Administration Medical Center
- Other Blood Establishment
For more detailed information please see the complete "Compliance Program Guidance Manual - Chapter 42 - Blood and Blood Products".
Related GMP News
29.05.2024New FDA Draft Guideline regarding the Use of Human- and Animal-derived Materials
22.05.2024New FDA Draft Guideline regarding Safety Testing of human allogeneic Cells
07.05.2024Final Approval of SoHO Regulation
07.05.2024FDA Warning Letter to a Biotechnology Company in China
07.05.2024Update of Guideline on Epidemiological Data
05.03.2024FDA Warning Letter on misbranded and unapproved Drugs